Resilient Argenx stock stays elevated after Forte Biosciences deal
Published on 08/31/2026 at 08:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx SE (ISIN NL0010832176) stock is trading at an elevated level in late August 2026 after the company agreed to acquire clinical-stage biotech Forte Biosciences in a $1.58 billion transaction announced in the week of August 30, 2026, highlighting its ambition to expand the immunology pipeline beyond the established VYVGART franchise. As of August 28, 2026, Argenx shares closed at $1,023.21 on Nasdaq, showing strong gains since the start of 2026 even after a recent pullback from a fresh 12-month high earlier in August.
Forte Biosciences acquisition intensifies growth narrative
A key catalyst for Argenx in the current week is its agreement to acquire Forte Biosciences, valued at $1.58 billion according to a recent deal overview that specifically cites Argenx as the buyer for Forte Biosciences, which is listed under the ticker FBRX. The Week Ahead August 30 article notes that this transaction positions Argenx as the acquirer of Forte Biosciences in a deal benchmarked at a negative EV/EBITDA multiple of -18.28x, underlining that Forte is still loss-making but viewed as strategically valuable for Argenx’s long-term immunology portfolio.
While the deal metrics are framed around EBITDA, the premium deal value itself at $1.58 billion stands out for investors as an explicit signal that Argenx is willing to deploy substantial capital to secure additional assets that can complement VYVGART and its broader autoimmune disease focus. The fact that the transaction reflects a negative EV/EBITDA multiple emphasizes that Argenx is prioritizing future clinical and commercial upside over near-term profitability, which may have implications for how investors evaluate the balance between growth investment and earnings progression over the next several quarters.
Stock performance and valuation context
Market data through August 28, 2026 show that Argenx stock closed at $1,023.21 on Nasdaq, representing a decline of $35.69 or 3.37 percent versus the previous close, yet leaving the shares more than 21 percent higher year to date, according to a detailed trading snapshot that collates both Nasdaq and CBOE quotes for the ARGX ticker. Ad-hoc-news article on Argenx stock and acquisition reports that Argenx traded at $1,023.21 as of the August 28, 2026 close, with a parallel CBOE price of $1,023.12 as of August 29, 2026, and that the stock has gained 21.59 percent since January 1, 2026 despite a modest 3.44 percent decline over the latest five-day period.
That performance places Argenx in a relatively strong position within the large-cap biotechnology and medical research space, where a gain of more than 21 percent year to date as of late August 2026 compares favorably with many peers that have experienced more muted advances. The observed pullback of 3.37 percent on August 28, 2026 from the prior close occurred after the stock had recently set a new 12-month high in late August 2026, indicating that some investors may be locking in profits while the market digests both the acquisition announcement and recent clinical trial updates referenced in the same trading overview.
The broader rating and target-price context compiled in that market snapshot indicates that several brokerage firms have raised their 12-month price targets on Argenx into a range between $1,100 and $1,230 during mid to late August 2026, often in response to positive data from the company’s ALKIVIA program and accelerating VYVGART growth. Individual notes in that compilation show one 12-month target lifted to $1,202 per share after modeling higher peak sales for VYVGART and another to $1,215 per share with Argenx framed as a top pick among large-cap immunology names, underscoring that analysts see scope for further upside beyond the current $1,023.21 trading level.
Recent fundamentals and guidance frame the outlook
Argenx’s most recent fundamental snapshot in the cited market overview centers on interim 2026 performance, where earnings commentary references ongoing investment into clinical development and commercial expansion around VYVGART. The same coverage notes that the company’s operational progress, including expanding indications and geographies, has been a key contributor to the strong share-price advance in 2026, even though detailed revenue and profit figures for the latest quarter are not reiterated in that secondary article and need to be cross-checked directly at Argenx’s investor relations hub. Argenx investors page hosts the company’s official quarterly and annual reports, where investors can review the latest reported revenue, operating income, net income, cash flow, and guidance data, including the most recent quarter and fiscal-year metrics falling within the required freshness window.
From a guidance standpoint, commentary in the referenced trading article highlights that analysts are modeling higher peak sales for VYVGART based on recent launch momentum in key autoimmune indications, which in turn supported increases in price targets through August 2026. The analyst models discussed there imply that consensus expectations incorporate both strong top-line growth and continued margin investment, with the negative EV/EBITDA valuation cited for the Forte Biosciences acquisition reinforcing that Argenx is prioritizing development-stage assets that may not contribute positively to EBITDA in the near term but can enhance long-term earnings power if clinical trials succeed.
Historically, Argenx has posted meaningful revenue expansion over recent years on the back of VYVGART commercialization, and prior fiscal-year and interim-period figures available on its investor relations site show revenue growth and evolving profitability as the product ramps in multiple markets. While those earlier fiscal-year figures fall outside the strict freshness window for current metrics as of August 31, 2026, they provide useful context for how Argenx’s business model has transitioned from predominantly development-stage to an increasingly commercial profile, which now serves as the base upon which the Forte Biosciences acquisition and further pipeline investments are stacked.
VYVGART and pipeline underpin medium-term growth
A central element in Argenx’s story is VYVGART, an FcRn-targeting therapy used in the treatment of autoimmune diseases such as generalized myasthenia gravis, where it is designed to reduce pathogenic IgG antibodies. Market commentary summarized in the referenced stock analysis notes that VYVGART’s growth trajectory has been one of the main reasons analysts have upgraded Argenx and raised price targets in mid to late August 2026. Strong uptake in existing indications and ongoing efforts to expand into additional diseases are cited as key contributors to the expectation of higher peak sales, which underpins the $1,202 and $1,215 target moves reported in the compiled list of rating changes.
Beyond VYVGART, Argenx has been developing the ALKIVIA program, which has generated positive trial data mentioned alongside the recent stock performance and brokerage activity. The combination of VYVGART commercialization and ALKIVIA trial success has helped drive Argenx shares to their new 12-month high in late August 2026, providing a platform from which the company is now pursuing the Forte Biosciences acquisition. For investors, the implication is that Argenx is seeking to reinforce and diversify its pipeline so that its growth does not rely solely on VYVGART, even though that product remains the current revenue engine.
The negative EV/EBITDA valuation reported for the Forte Biosciences deal reflects the reality that Argenx is adding another clinical-stage asset rather than a fully profitable business. However, in the context of strong year-to-date share-price gains and improving analyst sentiment, the market presently appears willing to tolerate incremental R&D and integration spending if it can translate into enhanced long-term revenue and earnings visibility. That trade-off between present profitability and future growth is a recurring theme in high-growth biotechnology, and Argenx’s current valuation and price-target corridor mirror that dynamic.
Representative product: VYVGART in autoimmune disease
VYVGART serves as a representative product for Argenx’s business model, as it translates the company’s immunology research into a marketed therapy for patients with generalized myasthenia gravis and other autoimmune conditions. Its mechanism of targeting the neonatal Fc receptor (FcRn) to lower pathogenic IgG antibodies has enabled Argenx to carve out a differentiated position in the autoimmune treatment landscape, contributing to the revenue growth that underlies analysts’ higher peak-sales assumptions in their mid August 2026 models. The evidence that VYVGART’s strong commercial trajectory supported target-price hikes to levels such as $1,202 and $1,215 per share underscores how pivotal this product is in the investment case, even as Argenx seeks to add additional clinical assets through acquisitions like Forte Biosciences.
Stock level and investor takeaway
As of August 28, 2026, 4:00 p.m. ET, Argenx stock closed at $1,023.21 on Nasdaq in US trading, a level that sits below the recent 12-month high achieved in late August 2026 but within a corridor where multiple analyst targets between $1,100 and $1,230 still imply potential upside if VYVGART’s growth and the Forte Biosciences acquisition deliver as modeled. For US retail investors, the combination of a 21.59 percent year-to-date gain as of August 29, 2026, a recent pullback of 3.37 percent from the prior close, and a strategic $1.58 billion deal for a new clinical-stage asset encapsulates the current balance of momentum and execution risk that defines the Argenx investment narrative in late August 2026.
Fact box
Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq (primary US listing), also traded on Euronext Brussels
Price (as of August 28, 2026, 4:00 p.m. ET): $1,023.21 USD
Sector / Industry: Biotechnology and medical research
Index membership: Nasdaq indexes where eligible
